Cargando…

Plasma big endothelin-1 is an effective predictor for ventricular arrythmias and end-stage events in primary prevention implantable cardioverter- defibrillator indication patients

OBJECTIVE: To investigate whether plasma big endothelin-1 (ET-1) predicts ventricular arrythmias (VAs) and end-stage events in primary prevention implantable cardioverter-defibrillator (ICD) indication patigents. METHODS: In total, 207 patients fulfilling the inclusion criteria from Fuwai Hospital b...

Descripción completa

Detalles Bibliográficos
Autores principales: LI, Xiao-Yao, ZHAO, Shuang, FAN, Xiao-Han, CHEN, Ke-Ping, HUA, Wei, LIU, Zhi-Min, XUE, Xiao-Di, ZHOU, Bin, ZHANG, Shu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Science Press 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7416061/
https://www.ncbi.nlm.nih.gov/pubmed/32863825
http://dx.doi.org/10.11909/j.issn.1671-5411.2020.07.003
_version_ 1783569253448810496
author LI, Xiao-Yao
ZHAO, Shuang
FAN, Xiao-Han
CHEN, Ke-Ping
HUA, Wei
LIU, Zhi-Min
XUE, Xiao-Di
ZHOU, Bin
ZHANG, Shu
author_facet LI, Xiao-Yao
ZHAO, Shuang
FAN, Xiao-Han
CHEN, Ke-Ping
HUA, Wei
LIU, Zhi-Min
XUE, Xiao-Di
ZHOU, Bin
ZHANG, Shu
author_sort LI, Xiao-Yao
collection PubMed
description OBJECTIVE: To investigate whether plasma big endothelin-1 (ET-1) predicts ventricular arrythmias (VAs) and end-stage events in primary prevention implantable cardioverter-defibrillator (ICD) indication patigents. METHODS: In total, 207 patients fulfilling the inclusion criteria from Fuwai Hospital between January 2013 and December 2015 were retrospectively analyzed. The cohort was divided into three groups according to baseline plasma big ET-1 tertiles: tertile 1 (< 0.38 pmol/L, n = 68), tertile 2 (0.38–0.7 pmol/L, n = 69), and tertile 3 (> 0.7 pmol/L, n = 70). The primary endpoints were VAs. The secondary endpoints were end-stage events comprising all-cause mortality and heart transplantation. RESULTS: During a mean follow-up period of 25.6 ± 13.9 months, 38 (18.4%) VAs and 78 (37.7%) end-stage events occurred. Big ET-1 was positively correlated with NYHA class (r = 0.165, P = 0.018), serum creatinine concentration (Scr; r = 0.147, P = 0.034), high-sensitivity C-reactive protein (hs-CRP; r = 0.217, P = 0.002), Lg NT-pro BNP (r = 0.463, P < 0.001), left ventricular end diastolic diameter (LVEDD; r = 0.234, P = 0.039) and negatively correlated with left ventricular ejection fraction (LVEF; r = −0.181, P = 0.032). Kaplan-Meier analysis showed that elevated big ET-1 was associated with increased risk of VAs and end-stage events (P < 0.05). In multivariate Cox regression models, big ET-1 was an independent risk factor for VAs (hazard ratio (HR) = 3.477, 95% confidence interval (CI): 1.352–8.940, P = 0.010, tertile 2 vs. tertile 1; HR = 4.112, 95% CI: 1.604–10.540, P = 0.003, tertile 3 vs. tertile 1) and end-stage events (HR = 2.804, 95% CI: 1.354–5.806, P = 0.005, tertile 2 vs. tertile 1; HR = 4.652, 95% CI: 2.288–9.459, P < 0.001, tertile 3 vs. tertile 1). CONCLUSIONS: In primary prevention ICD indication patients, plasma big ET-1 levels can predict VAs and end-stage events and may facilitate ICD-implantation risk stratification.
format Online
Article
Text
id pubmed-7416061
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Science Press
record_format MEDLINE/PubMed
spelling pubmed-74160612020-08-27 Plasma big endothelin-1 is an effective predictor for ventricular arrythmias and end-stage events in primary prevention implantable cardioverter- defibrillator indication patients LI, Xiao-Yao ZHAO, Shuang FAN, Xiao-Han CHEN, Ke-Ping HUA, Wei LIU, Zhi-Min XUE, Xiao-Di ZHOU, Bin ZHANG, Shu J Geriatr Cardiol Research Article OBJECTIVE: To investigate whether plasma big endothelin-1 (ET-1) predicts ventricular arrythmias (VAs) and end-stage events in primary prevention implantable cardioverter-defibrillator (ICD) indication patigents. METHODS: In total, 207 patients fulfilling the inclusion criteria from Fuwai Hospital between January 2013 and December 2015 were retrospectively analyzed. The cohort was divided into three groups according to baseline plasma big ET-1 tertiles: tertile 1 (< 0.38 pmol/L, n = 68), tertile 2 (0.38–0.7 pmol/L, n = 69), and tertile 3 (> 0.7 pmol/L, n = 70). The primary endpoints were VAs. The secondary endpoints were end-stage events comprising all-cause mortality and heart transplantation. RESULTS: During a mean follow-up period of 25.6 ± 13.9 months, 38 (18.4%) VAs and 78 (37.7%) end-stage events occurred. Big ET-1 was positively correlated with NYHA class (r = 0.165, P = 0.018), serum creatinine concentration (Scr; r = 0.147, P = 0.034), high-sensitivity C-reactive protein (hs-CRP; r = 0.217, P = 0.002), Lg NT-pro BNP (r = 0.463, P < 0.001), left ventricular end diastolic diameter (LVEDD; r = 0.234, P = 0.039) and negatively correlated with left ventricular ejection fraction (LVEF; r = −0.181, P = 0.032). Kaplan-Meier analysis showed that elevated big ET-1 was associated with increased risk of VAs and end-stage events (P < 0.05). In multivariate Cox regression models, big ET-1 was an independent risk factor for VAs (hazard ratio (HR) = 3.477, 95% confidence interval (CI): 1.352–8.940, P = 0.010, tertile 2 vs. tertile 1; HR = 4.112, 95% CI: 1.604–10.540, P = 0.003, tertile 3 vs. tertile 1) and end-stage events (HR = 2.804, 95% CI: 1.354–5.806, P = 0.005, tertile 2 vs. tertile 1; HR = 4.652, 95% CI: 2.288–9.459, P < 0.001, tertile 3 vs. tertile 1). CONCLUSIONS: In primary prevention ICD indication patients, plasma big ET-1 levels can predict VAs and end-stage events and may facilitate ICD-implantation risk stratification. Science Press 2020-07-28 2020-07-28 /pmc/articles/PMC7416061/ /pubmed/32863825 http://dx.doi.org/10.11909/j.issn.1671-5411.2020.07.003 Text en Copyright and License information: Journal of Geriatric Cardiology 2020 http://creativecommons.org/licenses/by-nc-sa/4.0/ This work is licensed under a Creative Commons Attribution-NonCommercial-Share Alike 4.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/4.0/
spellingShingle Research Article
LI, Xiao-Yao
ZHAO, Shuang
FAN, Xiao-Han
CHEN, Ke-Ping
HUA, Wei
LIU, Zhi-Min
XUE, Xiao-Di
ZHOU, Bin
ZHANG, Shu
Plasma big endothelin-1 is an effective predictor for ventricular arrythmias and end-stage events in primary prevention implantable cardioverter- defibrillator indication patients
title Plasma big endothelin-1 is an effective predictor for ventricular arrythmias and end-stage events in primary prevention implantable cardioverter- defibrillator indication patients
title_full Plasma big endothelin-1 is an effective predictor for ventricular arrythmias and end-stage events in primary prevention implantable cardioverter- defibrillator indication patients
title_fullStr Plasma big endothelin-1 is an effective predictor for ventricular arrythmias and end-stage events in primary prevention implantable cardioverter- defibrillator indication patients
title_full_unstemmed Plasma big endothelin-1 is an effective predictor for ventricular arrythmias and end-stage events in primary prevention implantable cardioverter- defibrillator indication patients
title_short Plasma big endothelin-1 is an effective predictor for ventricular arrythmias and end-stage events in primary prevention implantable cardioverter- defibrillator indication patients
title_sort plasma big endothelin-1 is an effective predictor for ventricular arrythmias and end-stage events in primary prevention implantable cardioverter- defibrillator indication patients
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7416061/
https://www.ncbi.nlm.nih.gov/pubmed/32863825
http://dx.doi.org/10.11909/j.issn.1671-5411.2020.07.003
work_keys_str_mv AT lixiaoyao plasmabigendothelin1isaneffectivepredictorforventriculararrythmiasandendstageeventsinprimarypreventionimplantablecardioverterdefibrillatorindicationpatients
AT zhaoshuang plasmabigendothelin1isaneffectivepredictorforventriculararrythmiasandendstageeventsinprimarypreventionimplantablecardioverterdefibrillatorindicationpatients
AT fanxiaohan plasmabigendothelin1isaneffectivepredictorforventriculararrythmiasandendstageeventsinprimarypreventionimplantablecardioverterdefibrillatorindicationpatients
AT chenkeping plasmabigendothelin1isaneffectivepredictorforventriculararrythmiasandendstageeventsinprimarypreventionimplantablecardioverterdefibrillatorindicationpatients
AT huawei plasmabigendothelin1isaneffectivepredictorforventriculararrythmiasandendstageeventsinprimarypreventionimplantablecardioverterdefibrillatorindicationpatients
AT liuzhimin plasmabigendothelin1isaneffectivepredictorforventriculararrythmiasandendstageeventsinprimarypreventionimplantablecardioverterdefibrillatorindicationpatients
AT xuexiaodi plasmabigendothelin1isaneffectivepredictorforventriculararrythmiasandendstageeventsinprimarypreventionimplantablecardioverterdefibrillatorindicationpatients
AT zhoubin plasmabigendothelin1isaneffectivepredictorforventriculararrythmiasandendstageeventsinprimarypreventionimplantablecardioverterdefibrillatorindicationpatients
AT zhangshu plasmabigendothelin1isaneffectivepredictorforventriculararrythmiasandendstageeventsinprimarypreventionimplantablecardioverterdefibrillatorindicationpatients